Veraxa Biotech AG

US$0.95As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:VRXAHealthcare
Country USA
PE (Fwd) •••
TSR 2Y CAGR (67.26%)
Div yield —
ROE (871.42%)
Biotechnology
Beta (5Y) 0.22
PE TTM —
TSR TTM (90.97%)
Mkt cap US$134.3M
ROIC (478.61%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.06
12.07%
4.74%
Hold 6|9|10|9|1
4Q25
1Q26
2Q26
3Q26
Earnings per shareFr
0.02
0.02
0.02
0.03
16.49%
27.39%
32.56%
38.32%
RevenueFr M
6.994
7.382
7.646
7.721
6.34%
6.94%
9.79%
8.43%
Peers (US$134.3M)
Cap (US$)
PE
279.8M
—
192.3M
—
134.3M
—
Capital
TTM
5Y
10Y
Leveragex
0.731
0.575
0.483
EBIT/Intx
0.850
0.337
0.325
Own earn%
(205.56)
28.89
49.95
Sh yield%
23.57
50.14
49.78
Owners
Insiders/Inst%
3.30
64.01
Short interest%
3.85
SBC / revenue%
1.75
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
24–29
$1 testx
0.0
Incr. ROIC%
15